

Supplementary data

Pd-catalysed intramolecular transformations of indolylbenzenesulfonamides: *ortho*-sulfonamido-bi(hetero)aryls via C2-arylation and polycyclic sultams via C3 arylation

*Rajnikanth Sunke,[#] Shabbir Ahmed Khan,[#] and K. C. Kumara Swamy**


[#]Equal contribution

School of Chemistry, University of Hyderabad, Hyderabad 500 046, Telangana, India

e-mail: kckssc@uohyd.ac.in, kckssc@yahoo.com

S. No	Contents	Page No.
1	Table S1: Iodine mediated synthesis of Indolylbenzene/thiophene sulfonamides 3 and 6	S2-S7
2	X-ray data collection, solution, refinement and the ORTEPs/crystal data of 5aa , 9ba , 9bh , 10al , 10bk and 12ag (Figures S1-S6)	S9-S11
3	¹ H and ¹³ C NMR spectra of all new compounds (Figures S7-S128) [order: 5aa-5dg ; 6aa-6ag ; 7 ; 8 ; 9aa-9dg ; 10aa-10dg ; 11 and 12aa-12ag]	S12-S72
4	HRMS for 5af , 9ae , 9bi , 12aa and 12ad	S73-S77
5	References	S78










Table S1: Iodine mediated synthesis of Indolyllbenzene/thiophene sulfonamides (**5**), (**6**), (**7**) and (**8**).^a




















(i) *General Procedure for the preparation of 1, 2a, 3, and 4:* 2-Iodo substituted sulfonamides **1** were prepared according to the procedure described in literature.¹ The compound 3-bromo-*N*-methylthiophene-2-sulfonamide **2a** was prepared according to a procedure described in the literature.² Other starting materials **3** & **4** were prepared *via* alkylation, benzylation and allylation of the corresponding indoles according to a known procedure.³









(ii) *General procedure for the preparation of iodo-substituted indolyllbenzene/thiophene sulfonamides 5aa-5dg, 6aa-6ag, 7, and 8:* An oven dried 25 mL round-bottomed flask was charged with sulfonamide **1** (0.32 mmol), Cs₂CO₃ (0.48 mmol) and I₂ (0.32 mmol) in acetonitrile (2.5 mL) added indole **3** (0.38 mmol). Then the mixture was stirred at rt (25 °C) under nitrogen for 5-8 h. After completion of the reaction (TLC), the reaction was quenched with a saturated solution of Na₂S₂O₃ (10 mL) and the mixture was treated with ethyl acetate (20 mL). The resulting solution was washed with water and the aqueous part extracted with ethyl acetate (2 x 20 mL). The combined organic layer was washed with saturated brine solution (2 x 20 mL), dried over anhydrous Na₂SO₄, and concentrated in vacuum. The








residue was then purified by using silica gel column chromatography using hexane-ethyl acetate (9:1) as eluent to afford the pure desired compounds **5**, **6**, **7** and **8**. Compounds **5aa-5dg**, **6aa-6ag**, **7** and **8** were prepared from the appropriate sulfonamide **1a-e**, **2a** and indole **3**, **4** by using the same procedure and the same molar quantities





Entry	Sulfonamide	Indole	Time/h	Product	Yield ^b (%)
1	 1a	 3a	5	 5aa	77
2	1a	 3b	6	 5ab	67
3	1a	 3c	5	 5ac	70
4	1a	 3d	7	 5ad	72

5	1a	 <p>3e</p>	6	 <p>5ae</p>	70
6	1a	 <p>3f</p>	5	 <p>5af</p>	67
7	1a	 <p>3h</p>	7	 <p>5ah</p>	82
8	1a	 <p>3i</p>	6	 <p>5ai</p>	81
9	1a	 <p>3j</p>	6	 <p>5aj</p>	77

10	1a	 3l	7	 5al	62
11	 1b	3a	7	 5ba	83
12	1b	3d	7	 5bd	71
13	1b	3e	6	 5be	77
14	1b	3h	6	 5bh	83

15	1b	3i	7	 5bi	79
16	1b	3j	6	 5bj	76
17	1b	 3k	5	 5bk	70
18	 1c	3d	6	 5cd	72
19	1c	 3g	7	 5cg	67

20	 <p>1d</p>	3d	7	 <p>5dd</p>	48
21	1d	3g	7	 <p>5dg</p>	60
22	 <p>2a</p>	3a		 <p>6aa</p>	82
23	2a	3d	8	 <p>6ad</p>	73
24	2a	3g	8	 <p>6ag</p>	80

25	1c	4	8	 7	68
26	 1e	 3m	8	 8	70

^aAll the reactions were carried out using **1** (0.32 mmol), **2** (0.38 mmol), I₂ (0.32 mmol) and Cs₂CO₃ (0.48 mmol) in acetonitrile (5.0 mL), at rt (25 °C) under nitrogen atmosphere.

^bIsolated yield.

1. X-ray data collection, solution, refinement and the ORTEPs/crystal data:

Single crystal X-ray data for crystals of compounds **5aa**, **9ba**, **9bh**, **10al**, **10bk** and **12ag** were collected on an X-ray diffractometer using Mo-K_α (λ = 0.71073 Å) radiation after mounting on glass fibers inside a brass pin in open air. The structures were solved by direct methods and refined by full-matrix least squares method using standard procedures; absorption corrections were done using SADABS program, where applicable [(a) Sheldrick, G. M. *SADABS, Siemens Area Detector Absorption Correction*, University of Gottingen, Germany, **1996**. (b) Sheldrick, G. M. *SHELX-97-A program for crystal structure solution and refinement*, University of Gottingen, **1997**. (c) Sheldrick, G. M. *SHELXTL NT Crystal Structure Analysis Package*, Bruker AXS, Analytical X-ray System, WI, USA, **1999**, version 5.10]. In general, all non-hydrogen atoms were refined anisotropically; hydrogen atoms were fixed by geometry or located by a Difference Fourier map and refined isotropically.

ORTEPs and crystal data of 5aa, 9ba, 9bh, 10al, 10bk and 12ag (Figures S1-S6)




Figure S1. ORTEP of **5aa** with 30% probability of ellipsoids: **Crystal data:** $C_{17}H_{17}IN_2O_2S$, $M = 440.29$, Monoclinic, Space group $P2_1/c$, $a = 6.2737(4)$, $b = 18.0774(6)$, $c = 16.6031(8)$ Å, $V = 1734.91(15)$ Å³, $\beta = 112.875(8)^\circ$, $Z = 4$, $\mu = 1.976$ mm⁻¹, data/restraints/parameters: 2513/0/212, R indices ($I > 2\sigma(I)$): $R1 = 0.0405$, $wR2$ (all data) = 0.1204. CCDC No: 2202000




Figure S2. ORTEP of **9ba** with 30% probability of ellipsoids: **Crystal data:** $C_{16}H_{16}N_2O_2S$, $M = 300.37$, Monoclinic, Space group $P2_1/n$, $a = 11.6333(5)$, $b = 11.3408(5)$, $c = 11.7715(5)$ Å, $V = 1523.13(11)$ Å³, $\beta = 101.2610(19)^\circ$, $Z = 4$, $\mu = 0.218$ mm⁻¹, data/restraints/parameters: 2683/0/193, R indices ($I > 2\sigma(I)$): $R1 = 0.0464$, $wR2$ (all data) = 0.1128. CCDC No: 2202001




Figure S3. ORTEP of **9bh** with 30% probability of ellipsoids: *Crystal data:* $C_{19}H_{22}N_2O_2S$, $M = 342.44$, Triclinic, Space group $P-1$, $a = 8.4303(4)$, $b = 10.1352(5)$, $c = 11.2583(4)$ Å, $V = 899.57(7)$ Å³, $\alpha = 80.979(4)^\circ$, $\beta = 71.424(4)^\circ$, $\gamma = 89.642(4)^\circ$, $Z = 2$, $\mu = 0.193$ mm⁻¹, data/restraints/parameters: 3131/0/224, R indices ($I > 2\sigma(I)$): $R1 = 0.0532$, $wR2$ (all data) = 0.1620. CCDC No: 2202002




Figure S4. ORTEP of **10al** with 30% probability of ellipsoids: *Crystal data:* $C_{22}H_{18}N_2O_2S$, $M = 374.44$, Monoclinic, Space group $P121/n1$, $a = 9.2441(3)$, $b = 9.3416(3)$, $c = 21.8748(6)$ Å, $V = 1884.83(10)$ Å³, $\beta = 93.805(3)^\circ$, $Z = 4$, $\mu = 0.191$ mm⁻¹, data/restraints/parameters: 3312/0/246, R indices ($I > 2\sigma(I)$): $R1 = 0.0535$, $wR2$ (all data) = 0.1430. CCDC No: 2202003




Figure S5. ORTEP of **10bk** with 30% probability of ellipsoids: *Crystal data:* C₁₉H₁₈N₂O₂S, *M* = 338.41, Orthorhombic, Space group *Pna2(1)*, *a* = 37.1188(12), *b* = 7.4217(2), *c* = 11.9822(5) Å, *V* = 3300.9(2) Å³, *Z* = 8, μ = 0.210 mm⁻¹, data/restraints/parameters: 5529/1/438, R indices (*I* > 2 σ (*I*)): R1 = 0.0578, *w*R2 (all data) = 0.1464. CCDC No: 2202004




Figure S6. ORTEP view of **12ag** with 30% probability of ellipsoids. *Crystal data:* C₁₆H₁₆N₂O₂S₂, *M* = 332.43, Monoclinic, Space group *P121/n1*, *a* = 10.3674(4), *b* = 7.8969(3), *c* = 19.6001(8) Å, *V* = 1568.26(11) Å³, α = 90°, β = 102.228(4)°, γ = 90°, *Z* = 4, μ = 0.347 mm⁻¹, data/restraints/parameters: 2772/0/202, R indices (*I* > 2 σ (*I*)): R1 = 0.0492, *w*R2 (all data) = 0.1387. CCDC No: 2202005.

2. ^1H and $^{13}\text{C}\{^1\text{H}\}$ NMR spectra of all new compounds




Figure S7. ^1H NMR spectrum of compound **5aa**




Figure S8. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **5aa**




Figure S9. $^1\text{H NMR}$ spectrum of compound **5ab**




Figure S10. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **5ab**




Figure S11. ^1H NMR spectrum of compound **5ac**




Figure S12. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **5ac**




Figure S13. ¹H NMR spectrum of compound **5ad**




Figure S14. ¹³C {¹H} NMR spectrum of compound **5ad**




Figure S15. ¹H NMR spectrum of compound **5ae**




Figure S16. ¹³C {¹H} NMR spectrum of compound **5ae**




Figure S17. ¹H NMR spectrum of compound **5af**




Figure S18. ¹³C{¹H} NMR spectrum of compound **5af**




Figure S19. ^1H NMR spectrum of compound **5ah**




Figure S20. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **5ah**




Figure S21. ^1H NMR spectrum of compound **5ai**




Figure S22. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **5ai**




Figure S23. ¹H NMR spectrum of compound **5aj**




Figure S24. ¹³C {¹H} NMR spectrum of compound **5aj**




Figure S25. ^1H NMR spectrum of compound **5al**






Figure S26. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **5al**






Figure S29. ¹H NMR spectrum of compound **5bd**




Figure S30. ¹³C {¹H} NMR spectrum of compound **5bd**




Figure S31. ¹H NMR spectrum of compound **5be**




Figure S32. ¹³C {¹H} NMR spectrum of compound **5be**




Figure S33. ^1H NMR spectrum of compound **5bh**




Figure S34. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **5bh**




Figure S35. ¹H NMR spectrum of compound **5bi**




Figure S36. ¹³C{¹H} NMR spectrum of compound **5bi**




Figure S37. ¹H NMR spectrum of compound **5bj**




Figure S38. ¹³C{¹H} NMR spectrum of compound **5bj**




Figure S39. ^1H NMR spectrum of compound **5bk**




Figure S40. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **5bk**




Figure S41. ¹H NMR spectrum of compound **5cd**




Figure S42. ¹³C {¹H} NMR spectrum of compound **5cd**




Figure S43. ^1H NMR spectrum of compound **5cg**




Figure S44. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **5cg**




Figure S45. ¹H NMR spectrum of compound **5dd**






Figure S46. ¹³C {¹H} NMR spectrum of compound **5dd**






Figure S49. ^1H NMR spectrum of compound **6aa**




Figure S50. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **6aa**




Figure S51. ¹H NMR spectrum of compound **6ad**




Figure S52. ¹³C {¹H} NMR spectrum of compound **6ad**




Figure S53. ^1H NMR spectrum of compound **6ag**




Figure S54. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **6ag**




Figure S55. ^1H NMR spectrum of compound **7**




Figure S56. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **7**




Figure S57. ¹H NMR spectrum of compound **8**




Figure S58. ¹³C {¹H} NMR spectrum of compound **8**




Figure S59. ^1H NMR spectrum of compound **9aa**




Figure S60. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **9aa**




Figure S61. ¹H NMR spectrum of compound **9ab**




Figure S62. ¹³C {¹H} NMR spectrum of compound **9ab**




Figure S63. ^1H NMR spectrum of compound **9ac**




Figure S64. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **9ac**




Figure S65. ¹H NMR spectrum of compound **9ad**




Figure S66. ¹³C {¹H} NMR spectrum of compound **9ad**




Figure S67. ¹H NMR spectrum of compound **9ae**




Figure S68. ¹³C {¹H} NMR spectrum of compound **9ae**




Figure S69. ¹H NMR spectrum of compound **9ah**




Figure S70. ¹³C {¹H} NMR spectrum of compound **9ah**




Figure S71. ¹H NMR spectrum of compound **9ai**




Figure S72. ¹³C{¹H} NMR spectrum of compound **9ai**




Figure S73. ¹H NMR spectrum of compound **9aj**




Figure S74. ¹³C{¹H} NMR spectrum of compound **9aj**




Figure S75. ^1H NMR spectrum of compound **9ba**




Figure S76. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **9ba**




Figure S77. ^1H NMR spectrum of compound **9bd**




Figure S78. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **9bd**




Figure S79. ¹H NMR spectrum of compound **9be**




Figure S80. ¹³C{¹H} NMR spectrum of compound **9be**




Figure S81. ¹H NMR spectrum of compound **9bh**




Figure S82. ¹³C {¹H} NMR spectrum of compound **9bh**




Figure S83. ¹H NMR spectrum of compound **9bi**




Figure S84. ¹³C{¹H} NMR spectrum of compound **9bi**




Figure S85. ¹H NMR spectrum of compound **9bj**




Figure S86. ¹³C {¹H} NMR spectrum of compound **9bj**




Figure S87. ^1H NMR spectrum of compound **9bk**




Figure S88. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **9bk**




Figure S89. ^1H NMR spectrum of compound **9cd**




Figure S90. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **9cd**




Figure S91. ^1H NMR spectrum of compound **9dd**




Figure S92. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **9dd**




Figure S93. ^1H NMR spectrum of compound **9dg**




Figure S94. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **9dg**




Figure S95. ^1H NMR spectrum of compound **10aa**




Figure S96. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **10aa**




Figure S97. ^1H NMR spectrum of compound **10ac**




Figure S98. ^{13}C $\{^1\text{H}\}$ NMR spectrum of compound **10ac**




Figure S99. ^1H NMR spectrum of compound **10ae**




Figure S100. ^{13}C $\{^1\text{H}\}$ NMR spectrum of compound **10ae**




Figure S101. ¹H NMR spectrum of compound **10af**




Figure S102. ¹³C {¹H} NMR spectrum of compound **10af**




Figure S103. ^1H NMR spectrum of compound **10al**




Figure S104. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **10al**




Figure S105. ^1H NMR spectrum of compound **10ba**




Figure S106. ^{13}C { $^1\text{H}}$ NMR spectrum of compound **10ba**




Figure S107. ^1H NMR spectrum of compound **10bd**




Figure S108. ^{13}C $\{^1\text{H}\}$ NMR spectrum of compound **10bd**




Figure S109. ^1H NMR spectrum of compound **10bj**




Figure S110. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **10bj**




Figure S111. ^1H NMR spectrum of compound **10bk**




Figure S112. ^{13}C { $^1\text{H}}$ NMR spectrum of compound **10bk**




Figure S113. ^1H NMR spectrum of compound **10cd**




Figure S114. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **10cd**




Figure S115. ¹H NMR spectrum of compound **10cg**




Figure S116. ¹³C {¹H} NMR spectrum of compound **10cg**




Figure S117. ¹H NMR spectrum of compound **10dd**




Figure S118. ¹³C {¹H} NMR spectrum of compound **10dd**




Figure S119. ^1H NMR spectrum of compound **10dg**




Figure S120. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **10dg**




Figure S121. ^1H NMR spectrum of compound **11**




Figure S122. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **11**




Figure S123. ^1H NMR spectrum of compound **12aa**




Figure S124. $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of compound **12aa**




Figure S125. ¹H NMR spectrum of compound **12ad**




Figure S126. ¹³C {¹H} NMR spectrum of compound **12ad**




Figure S127. ¹H NMR spectrum of compound 12ag




Figure S128. ¹³C {¹H} NMR spectrum of compound 12ag

Display Report

Analysis Info

Analysis Name E:\2021-data\PROF.KCK\SEPT\SAK-4.d
Method tune_low.m
Sample Name SAK-4
Comment

Acquisition Date 14-09-2021 13:01:44
Operator BDAL
Instrument maXis 255552.10138

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Not active	Set Capillary	4000 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1500 m/z	Set Charging Voltage	0 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C




Figure S129. HRMS (ESI) of compound **5af**

Display Report

Analysis Info

Analysis Name E:\2021-data\PROF.KCK\JULY-2021\SAK-286R.d
Method tune_low_PosR.m
Sample Name SAK-286R
Comment

Acquisition Date 03-07-2021 11:47:34

Operator BDAL
Instrument maXis 255552.10138

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Not active	Set Capillary	2800 V	Set Dry Heater	250 °C
Scan Begin	300 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	2500 m/z	Set Charging Voltage	0 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C




Figure S130. HRMS (ESI) of compound **9ae**

Display Report

Analysis Info

Analysis Name E:\2021-data\PROF.KCK\JULY-2021\RAJ-176.d
Method tune_low_Pos-R2.m
Sample Name RAJ-176
Comment

Acquisition Date 03-07-2021 12:00:14

Operator BDAL
Instrument maXis 255552.10138

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Not active	Set Capillary	2800 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	2580 m/z	Set Charging Voltage	0 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C




Figure S131. HRMS (ESI) of compound 9bi

Display Report

Analysis Info		Acquisition Date	2/9/2021 4:24:06 PM
Analysis Name	D:\Data\1\1\1\Finaltest\2021\PROF.KCK\FEB\RAJ-THIO-MR1.d	Operator	BDAL@DE
Method	tune_low.m	Instrument	maXis 10138
Sample Name	RAJ-THIO-MR1		
Comment			

Acquisition Parameter					
Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Not active	Set Capillary	4000 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	1500 m/z	Set Collision Cell RF	350.0 Vpp	Set Divert Valve	Waste




Figure S132. HRMS (ESI) of compound 12aa

Display Report

Analysis Info

Analysis Name D:\Data\1\Data\Finaltest\2021\PROF.KCK\FEB\RAJ-270.d
Method tune_low.m
Sample Name RAJ-270
Comment

Acquisition Date 2/11/2021 2:39:19 PM

Operator BDAL@DE
Instrument maXis 10138

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.3 Bar
Focus	Not active	Set Capillary	4200 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	6.0 l/min
Scan End	1500 m/z	Set Collision Cell RF	350.0 Vpp	Set Divert Valve	Waste




Figure S133. HRMS (ESI) of compound 12ad

References

- (1) Sandeep, K.; Reddy, A. S.; Swamy, K. C. K. Cu(I) catalysed annulation of isothiocyanates/isocyanates with 2-iodo-sulfonamides: synthesis of benzodithiazines, benzothiadiazinones, benzothiazinylidene-anilines and benzothiazolyidene-anilines. *Org. Biomol. Chem.* **2019**, *17*, 6880 (and references cited therein).
- (2) Barange, D. K.; Kavala, V.; Kuo, C. -W.; Wang, C.-C.; Rajawinslin, R. R.; Donala, J.; Yao, C. -Fa. Regioselective synthesis of thiophene fused sultam derivatives via iodocyclization approach and their application towards triazole linker. *Tetrahedron Lett.* **2014**, *70*, 7598.
- (3) Merlic, C. A.; You, Y.; McInnes, D. M.; Zechman, A. L.; Miller, M. M.; Deng, Q. Benzannulation reactions of Fischer carbene complexes for the synthesis of indolocarbazole. *Tetrahedron* **2001**, *57*, 5199.